A Step Ahead in Metastatic Renal Cell Carcinoma.
Published in The New England journal of medicine
Published in The New England journal of medicine
Published in The New England journal of medicine
Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear. In this phase 3 trial, we randomly assigned (in a 1:1:1 ratio) patients with advanced renal cell carcinoma and no previous systemic therapy to receive lenvatinib...
Published in The New England journal of medicine
Published in The New England journal of medicine
Published in The New England journal of medicine
Published in The New England journal of medicine
Published in The New England journal of medicine
Published in The New England journal of medicine
Published in The New England journal of medicine
Published in The New England journal of medicine